Why proteasome inhibitors cannot ERADicate multiple myeloma.
about
Clinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyArtesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosisMiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma.Mitochondrial-Targeted Decyl-Triphenylphosphonium Enhances 2-Deoxy-D-Glucose Mediated Oxidative Stress and Clonogenic Killing of Multiple Myeloma CellsThe Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaTreatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.Identification of Long Non-Coding RNAs Deregulated in Multiple Myeloma Cells Resistant to Proteasome Inhibitors.Overcoming bortezomib resistance in multiple myeloma.Which therapies will move to the front line for multiple myeloma?In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Transcriptional repression by the HDAC4-RelB-p52 complex regulates multiple myeloma survival and growth.Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
P2860
Q28080999-980AF9D6-CB05-4EB7-89F2-D839C7EDC554Q28082910-58B9E66B-4577-4801-9B5E-5492E0F9E6B9Q28393215-8DB300A4-2C8D-4C7B-A11A-69EAEC1852E8Q35178969-1CC85EEA-AD5B-4079-882F-76A7AF5BCFDAQ35550181-298CFFDB-34E3-49BE-800B-FDAF18BA4FBCQ36146344-14CFCDF7-17CD-4783-90ED-405A58482908Q36208283-314772CF-5533-4913-B2DB-E79FD251E464Q36444233-A1F47BB5-0255-47B4-A7EE-EE0BD7375652Q36750467-23E856DD-E94D-44FF-B77F-051A5E948083Q37171812-5D4DD691-0B20-4732-A14B-7AEED03FFFAAQ37373624-FEB9722F-4890-437C-B693-1FCFFDCB3172Q38238610-27EF5F8A-CFE9-4699-AD25-CED7D5BBBBFDQ38733592-F534F61D-3316-4E16-9B5E-494E153536E0Q38910971-779CE3F7-36F8-4904-81F0-44FE6F9429DDQ46667078-5393D6C6-F660-481A-B84C-B049552181E0Q55029794-1F67B046-4D1A-43E9-80DE-83DDC0DB8E9D
P2860
Why proteasome inhibitors cannot ERADicate multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@en
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@nl
type
label
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@en
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@nl
prefLabel
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@en
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@nl
P2860
P1433
P1476
Why proteasome inhibitors cannot ERADicate multiple myeloma.
@en
P2860
P304
P356
10.1016/J.CCR.2013.08.014
P577
2013-09-01T00:00:00Z